Montelukast to reduce heart damage after heart attack
Treatments studied
Part of Heart & circulation, Immune system & allergy clinical trials.
This study tests whether montelukast (a medication that reduces inflammation) can limit heart damage when given immediately after a sudden heart attack. Researchers will measure inflammation markers and heart injury to see if this drug helps patients recover better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 30 and 75 years old
- Diagnosed with a sudden, severe heart attack (STEMI) within the last 6 hours
- Receiving emergency treatment with angioplasty or clot-busting medication
- No ongoing use of anti-inflammatory drugs like steroids or NSAIDs
- Normal kidney and liver function
- Not allergic to montelukast
- Not in cardiogenic shock or with severe heart failure at enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This study tests a new drug called ziltivekimab to see if it helps people who have recently had a heart attack. The drug is given as an injection and compared to a placebo (a shot with no active medicine).
This trial tests whether combining antioxidant supplements with standard heart attack care can reduce heart muscle damage. It may help people who are getting emergency treatment for their first heart attack.
This trial tests if a newer acid-reducing drug is better than standard care for preventing stomach problems in people who recently had a heart attack and a stent placed. It could help those who need stomach protection while on blood thinners.
This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.
This trial tests whether the supplement L-carnitine, given during a heart attack procedure, can reduce heart muscle damage. If you are having a STEMI heart attack and are getting angioplasty, you may be able to join.
Hear when a new Acute Myocardial Infarction (AMI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.